Cargando…
Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers
The impressive but sad list of over forty clinical studies using various cytotoxic chemotherapies published in the last few years has failed to increase median survival of glioblastoma beyond two years after diagnosis. In view of this apparent brick wall, adjunctive non-cytotoxic growth factor block...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Termedia Publishing House
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444449/ https://www.ncbi.nlm.nih.gov/pubmed/26034396 http://dx.doi.org/10.5114/wo.2015.51421 |